Sign in
4

Changes in Ownership

CORCEPT THERAPEUTICS INC Filed Acc 0001193125-26-274224

Chief Financial Officer sold 40,000 shares at an average $81.15 ($3,245,900)

  • Chief Financial Officer acquired 40,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Mokari Atabak · Chief Financial Officer

Table I: Non-derivative

5 lines
Date Transaction Shares Price Value Owned after D/I
2026-06-15 Exercise or conversion : show line 1 in the form 10b5-1 +40,000 $19.26 $770,400 56,130 D
2026-06-15 Sale : show line 2 in the form 10b5-1 −9,434 $80.02 $754,924 46,696 D
2026-06-15 Sale : show line 3 in the form 10b5-1 −11,081 $80.94 $896,923 35,615 D
2026-06-15 Sale : show line 4 in the form 10b5-1 −19,483 $81.81 $1,593,889 16,132 D
2026-06-15 Sale : show line 5 in the form 10b5-1 −2 $82.45 $165 16,130 D
Open-market sales · 40,000 sh · avg $81.15 · $3,245,900

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-06-15 Exercise or conversion : show line 6 in the form 10b5-1 Stock option (right to buy) −40,000 20,000 D
Loading xslF345X06/ownership.xml…